Oncology

Friday, October 30, 2026

1

FDA Grants Priority Review to Sac-TMT for Endometrial Cancer

2

Updated ASTRO Guideline on Hypofractionated EBRT for Prostate Cancer

3

PET-Guided Strategy Lets Some HER2-Positive Patients Omit Chemotherapy

Thursday, October 29, 2026

1

Pembrolizumab Plus SBRT Fails to Improve EFS in Early-Stage NSCLC

2

AbbVie Seeks FDA Approval of Etentamig in Relapsed/Refractory Multiple Myeloma

3

Risk Strategy Could Defer Nearly Half of Immediate Biopsies for PI-RADS 3 Prostate Lesions

4

GLP-1 RA Prescribing in Older Adults With Diabetes and Cancer Tied Mainly to Metabolic Risk

Wednesday, October 28, 2026

1

Pembrolizumab Prolongs PFS vs Chemotherapy in dMMR Endometrial Cancer

2

Dalmelitinib Plus Aumolertinib Prolongs PFS in EGFR-Mutated, MET-Amplified NSCLC

Tuesday, October 27, 2026

1

FDA Approves Pfizer's Talzenna Plus Enzalutamide for HRR-Mutated Metastatic Prostate Cancer

2

Novartis: Adjuvant Kisqali Shows OS Benefit in HR+/HER2- Early Breast Cancer

3

AstraZeneca's Imfinzi Plus Enfortumab Vedotin Improves Survival in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

4

Anbenitamab Plus HB1801 Improves PFS vs THP in HER2-Positive Advanced Breast Cancer

Monday, October 26, 2026

1

Adding Imdelltra to Imfinzi as First-Line Maintenance Extends Survival in ES-SCLC

2

Trastuzumab Rezetecan Extends Progression-Free Survival in ERBB2-Low Advanced Breast Cancer

3

Nivolumab Plus Relatlimab Maintains PFS and OS Advantage Over Nivolumab in Advanced Melanoma

4

DOAC Use for Cancer-Associated VTE Doubled but Still Lagged Non-Cancer Use

Friday, October 23, 2026

1

Merck and Moderna Announced mRNA-based Therapy Reduced Recurrence and Death in Melanoma

2

Longer Denosumab Use in Bone-Metastatic Prostate Cancer Tied to More ONJ

3

Assisted Reproductive Technology Linked to Modestly Higher Childhood Cancer Risk

4

Urologists Prescribing More Oral Targeted Therapies for Advanced Prostate Cancer as Comanagement Declines

Thursday, October 22, 2026

1

ARIs Linked to Longer Survival Than Abiraterone in Metastatic Hormone-Sensitive Prostate Cancer

2

Fewer Punctures With Generative AI vs CBCT Guidance for Lung Biopsy

3

Immediate Test Result Release Rarely Increased Patient Anxiety in Portal Survey

4

Perioperative EV-Pembrolizumab Likely to be Cost-Effective and Extend Survival in Cisplatin-Ineligible MIBC

Wednesday, October 21, 2026

1

16-Fraction Postmastectomy Radiotherapy Noninferior to Conventional Regimen in Breast Cancer

2

Early Skin Toxicity May Signal Benefit From EV-Pembrolizumab in Retrospective Study

Tuesday, October 20, 2026

1

FDA Grants Accelerated Approval to Jemperli for Locally Advanced Rectal Cancer

2

Carboplatin Allocation Decisions Did Not Align With Health System Policy During Shortage

Monday, October 19, 2026

1

Cervical Cancer Screening Rose Through 2024, but Racial and Regional Gaps Persist

Loading